CSL pays Alentis $355 million upfront to co-develop claudin-1 antibody lixudebart

CSL has agreed to pay Alentis Therapeutics US$355 million upfront to co-develop and co-promote lixudebart, a phase 2 antibody against claudin-1, in a global deal the two companies announced on 4 October 2026 ¹. Alentis, a private biotech based in Basel, is also eligible for up to US$1.2 billion in commercial milestones ¹.

The terms

Under the agreement the Australian group pays for the remaining development work as well as the upfront fee. CSL will fully fund completion of the ongoing Phase 2 RENAL trial and a planned Phase 3 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), plus Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC) ¹. Once the drug is on the market, CSL takes 55% of global profits and Alentis 45% ¹².

The clinical case behind the price is small so far. An interim analysis of 26 patients with AAV-RPGN in the RENAL trial showed what the companies call "promising improvement in kidney function", measured by eGFR and proteinuria at 24 weeks ¹². A separate Phase 1b study, FEGATO, in 41 patients with advanced F3/F4 liver fibrosis, showed improved liver function at 6 weeks ¹. Both studies showed dose-dependent target engagement and, according to the companies, a favourable safety profile ¹. AAV-RPGN is a rare autoimmune disease in which most patients lose significant or total kidney function despite strong immunosuppression ¹.

Lixudebart binds exposed claudin-1, which the companies describe as a driver of inflammatory and fibrotic signalling in the kidney, liver, lung and other organs ¹. The FDA has granted it Orphan Drug designation in idiopathic pulmonary fibrosis ¹.

What it means for the market

For CSL the deal is a bet on nephrology. The company already sells kidney disease medicines including the anaemia drugs Mircera and Retacrit, the phosphate binder Velphoro and the pruritus treatment Korsuva ². Bill Mezzanotte, head of R&D at CSL, tied the agreement to the company's "commitment to building a leading global nephrology franchise" and to its "strategic intent to create high-value external partnerships" ¹. Fierce Biotech notes that CSL changed chief executive earlier this year after a fall in profits ², which puts external licensing at the centre of how it rebuilds growth.

The structure matters for biotech investors. A shared-profit co-development deal, with the partner carrying trial costs, lets Alentis keep 45% of the economics instead of taking royalties. Mark Pruzanski, chief executive of Alentis, said the partnership would let the company advance lixudebart "in several indications in parallel" and support its other clinical and preclinical programmes ¹. Those include two claudin-1 antibody-drug conjugates, ALE.P02 and ALE.P03, now in Phase 1/2 studies in solid tumours, with ALE.P02 holding FDA Fast Track designation ¹.

For developers working in fibrosis, the payment puts a market price on claudin-1 as a target while the human data remain early. Pruzanski described the deal as further validation of claudin-1 as a target ¹.

Caveats

The efficacy evidence is an interim look at 26 patients and a 41-patient Phase 1b study, reported by the companies rather than in peer-reviewed form ¹. The US$1.2 billion is tied to commercial milestones and depends on the drug reaching the market ¹². The next step is completion of the Phase 2 RENAL trial, followed by the planned Phase 3 trial in AAV-RPGN that CSL has agreed to fund ¹.